Physician profile
Eric Ranon
NPI 1861476137
$2,674.07
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.03 · 2020: $26.47 · 2021: $1,052 · 2022: $851 · 2023: $628 · 2024: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.66 | 2021-2024 | |
| Lilly USA, LLC | $264.31 | 2021-2023 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $242.29 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $224.93 | 2021-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $167.88 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $133.43 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $125.08 | 2021-2022 | |
| Abbott Laboratories | $123.75 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $85.64 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $85.34 | 2021-2022 | |
| Dexcom, INC. | $80.78 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $76.71 | 2021-2023 | Gvoke Hypopen |
| Amgen INC. | $68.05 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.72 | 2022 | |
| Astellas Pharma US INC | $53.15 | 2021-2024 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $48.50 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $40.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2021 | |
| Evoke Pharma, INC. | $37.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.62 | 2022 | |
| Lifescan, INC. | $35.28 | 2022-2023 | |
| Glaxosmithkline, LLC. | $32.83 | 2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.98 | 2022 | |
| Medtronic USA, INC. | $26.47 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.66 | 2023 | Voquezna |
| Rigel Pharmaceuticals, INC. | $18.25 | 2024 | Tavalisse, Rezlidhia |
| Medtronic, INC. | $16.45 | 2021 | |
| Esperion Therapeutics, INC. | $15.78 | 2021 | |
| Shield Therapeutics INC | $15.14 | 2024 | |
| Smith+Nephew, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ranon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.